The stock's rise snapped a three-day losing streak.
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...
This was the stock's third consecutive day of losses.
Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric ...
Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...
Arsenal Biosciences announced that Bristol Myers Squibb has exercised its exclusive license option for ArsenalBio’s AB-4000 series, the lead collaboration program generated unde ...
First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...
Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...
Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.